Formosa Pharmaceuticals, Cristália forge licensing deal for APP13007 in Brazil
Formosa Pharmaceuticals, a leading Taiwan-based pharmaceutical company, has announced a landmark licensing agreement with Cristália Produtos Químicos Farmacêuticos LTDA. This deal grants Cristália exclusive rights in Brazil for the commercialization of APP13007, a novel treatment for post-ocular surgery inflammation and pain. APP13007 Awaiting FDA Approval, Eyeing Brazilian Market Currently undergoing review by the U.S. Food […]